Scaling Fed-batch and Perfusion Processes for Antibody Production in Stirred Bioreactors with Geometrically Different Designs

Pepin Cenk^*
*Correspondence: Pepin Cenk, Department of Pharmaceutical Sciences, São Paulo University, Ribeirão Preto, Brazil, Email:

Introduction

The production of Monoclonal Antibodies (mAbs) has become a cornerstone in modern therapeutics, offering solutions for a variety of diseases, ranging from cancers to autoimmune disorders. As the demand for antibody-based drugs increases, so does the need for more efficient and scalable production processes. Bioreactors, particularly stirred-tank reactors, play a pivotal role in the manufacturing of mAbs. While there is a clear understanding of the importance of optimizing bioreactor performance, the challenges of scaling up fed-batch and perfusion processes in geometrically dissimilar stirred bioreactors are often underestimated. Stirred-tank bioreactors are the workhorses of industrial-scale cell culture for antibody production, particularly in mammalian cell cultures that express recombinant proteins. These bioreactors are designed to provide controlled environments for cells to grow and produce the desired antibody. However, the scaling of processes such as fed-batch and perfusion cultures presents unique challenges, particularly when transferring these processes across bioreactors with different geometries. Differences in geometry, such as the size and shape of the vessel, the position and design of the impeller, and the flow dynamics, can significantly impact mass transfer, mixing, and nutrient distribution within the bioreactor, all of which affect cell growth and protein production. Therefore, optimizing these processes in geometrically dissimilar bioreactors is essential to ensure that the scale-up is not only feasible but also efficient and costeffective.

Description

Fed-batch culture is one of the most widely used techniques for the industrial production of mAbs. In this process, nutrients are fed to the culture continuously or in pulses to maintain optimal growth conditions over an extended period, without introducing new volume. The aim is to prevent nutrient depletion, minimize waste product accumulation, and prolong the cell's productive phase to maximize antibody yields. Scaling fed-batch processes from laboratory to production scale is inherently complex because of the nonlinear relationship between reactor size and parameters such as oxygen transfer, mixing, and shear stress. The challenges in scaling fed-batch systems arise primarily from the dynamic and heterogenous nature of cell cultures. As the reactor volume increases, so do the variations in nutrient distribution, pH, and oxygen levels, which are often exacerbated by the design differences in bioreactors. For instance, in small-scale reactors, the interaction between the impeller and the culture medium is relatively straightforward and uniform. However, as the scale increases, the complex interplay of flow patterns, turbulence, and shear forces becomes more difficult to control, particularly when the geometry of the reactor is altered. Geometrically dissimilar bioreactors can have very different impeller designs, baffles, and mixing mechanisms, all of which impact the efficiency of nutrient and oxygen delivery to the cells, ultimately affecting cell metabolism and antibody production. These differences must be carefully studied and accounted for when scaling up fed-batch processes [1].

Perfusion cultures offer another potential solution for enhancing antibody production, particularly when high cell densities are required. In perfusion processes, cells are continuously supplied with fresh medium while spent medium is removed, thus maintaining optimal growth conditions. This system supports higher cell densities compared to batch and fed-batch processes and can be more efficient for antibody production over long cultivation periods. However, the implementation of perfusion systems is not without its challenges. When scaling perfusion processes across geometrically dissimilar stirredtank bioreactors, there are concerns about maintaining effective perfusion rates, adequate mixing, and minimizing shear stress. Unlike batch cultures, where the reactor is filled with a fixed volume of medium, perfusion processes require the continuous addition and removal of liquid, which can introduce additional complexity in larger reactors. Different bioreactor geometries may alter the fluid dynamics and lead to uneven perfusion, impacting the uniformity of cell growth and antibody production. In both fed-batch and perfusion processes, the key to successful scaling lies in understanding and optimizing the hydrodynamics within the bioreactor. The shear forces generated by the impeller, the level of turbulence, and the distribution of nutrients all play critical roles in cell growth, product formation, and the overall health of the culture [2].

As bioreactor geometry changes, these factors can significantly alter the behavior of the culture. For example, in larger reactors, increased mixing and turbulence can lead to higher shear stress, which may damage delicate mammalian cells and negatively affect productivity. Conversely, insufficient mixing or poorly designed flow patterns can result in nutrient gradients, leading to areas of the culture where cells are starved or unable to properly proliferate. Achieving a balance between efficient mixing, minimal shear stress, and optimal nutrient distribution is crucial when scaling up antibody production processes from small laboratory-scale reactors to large-scale production bioreactors. The solution to these scaling challenges lies in a combination of computational modeling, experimental optimization, and design considerations. Advances in computational fluid dynamics (CFD) have provided powerful tools for simulating the behavior of fluids within bioreactors, allowing for the prediction of flow patterns, shear forces, and nutrient distribution in different bioreactor designs. By using CFD, researchers can gain insights into the dynamics of the culture without the need for large-scale trials, saving both time and resources. Moreover, CFD can be used to test various bioreactor designs virtually, enabling the identification of the most optimal design for specific fed-batch or perfusion processes [3].

Experimental optimization also plays a significant role in overcoming the challenges of scaling. When transferring processes from small-scale laboratory reactors to larger, production-scale bioreactors, it is essential to perform pilotscale experiments to fine-tune parameters such as agitation speed, gas flow rates, and feeding strategies. These experiments can help identify potential scaling issues related to fluid dynamics and optimize the conditions for maximum cell growth and protein production. The data collected from pilotscale experiments can then be used to refine computational models and further optimize the scaling process. Despite the potential for computational modeling and experimental optimization, practical considerations in scaling fed-batch and perfusion processes often involve trade-offs between economic and performance goals. Bioreactor design and scaling are expensive endeavors, requiring significant investment in both time and resources. There is a continuous push to improve process efficiency and reduce costs, and achieving this requires careful consideration of not only the geometry of the bioreactor but also the operational parameters that impact production. For instance, scaling up might necessitate changes in feeding strategies, media formulations, and process monitoring, all of which contribute to the cost and complexity of the process. Additionally, the regulatory environment surrounding the production of mAbs requires that each scale-up step be carefully documented, tested, and validated, ensuring that the scaled process maintains the same product quality and consistency as the smaller-scale version [4,5].

Conclusion

Scaling fed-batch and perfusion antibody production processes in geometrically dissimilar stirred bioreactors represents a significant challenge in the biopharmaceutical industry. While the technical hurdles of scaling can be daunting, they are not insurmountable. By combining computational modeling, experimental optimization, and a deep understanding of hydrodynamics and bioreactor design, it is possible to overcome the challenges posed by geometric dissimilarities in bioreactors and ensure efficient and cost-effective production of monoclonal antibodies. However, this process requires not only scientific and engineering expertise but also a recognition of the economic and regulatory constraints that come with scaling production. By addressing these challenges effectively, the industry can meet the growing demand for antibody-based therapies and continue to improve the availability of these life-saving treatments.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Wong, H. Edward, Chun Chen, Huong Le and Chetan T. Goudar. "From chemostats to high‐density perfusion: The progression of continuous mammalian cell cultivation." J Chem Technol Biotechnol 97 (2022): 2297-2304.

Google Scholar, Crossref

2. Matanguihan, Cary and Paul Wu. "Upstream continuous processing: Recent advances in production of biopharmaceuticals and challenges in manufacturing." Curr Opin Biotechnol 78 (2022): 102828.

Google Scholar, Crossref, Indexed at

3. Bausch, Mona, Christian Schultheiss and Jochen B. Sieck. "Recommendations for comparison of productivity between fed‐batch and perfusion processes." Biotec J 14 (2019): 1700721.

Google Scholar, Crossref, Indexed at

4. Bielser, Jean-Marc, Loïc Chappuis, Yashi Xiao and Jonathan Souquet, et al. "Perfusion cell culture for the production of conjugated recombinant fusion proteins reduces clipping and quality heterogeneity compared to batch-mode processes." J Biotechnol 302 (2019): 26-31.

Google Scholar, Crossref, Indexed at

5. Arnold, Lindsay, Kenneth Lee, Joanna Rucker‐Pezzini and Jeong H. Lee. "Implementation of fully integrated continuous antibody processing: Effects on productivity and COGm." Biotec J A 14 (2019): 1800061.

Google Scholar, Crossref, Indexed at